Year-end report 2011

Year-end report 2011

For the fourth quarter, October - December

  · Net sales for the quarter were SEK 27.5 million (20.0), an increase of 37.5
percent year on year. The quarter’s results included full sales figures from
Olerup GmbH, which was consolidated into the group as of June 1, 2011.
  · Operating loss (EBIT) for the quarter was SEK 76.0 million (-4.0). The
results were impacted by the impairment of intangible assets of SEK 74.6
million.
  · Loss after tax was SEK 72.6 million (-5.3).
  · Loss per share basic and diluted was SEK 0.75 (-0.07).

For the January – December period

  · Net sales for the year amounted to SEK 98.7 million (80.5), an increase of
22.6 percent.
  · Operating loss (EBIT) for the year was SEK 88.1 million (-8.1).
Non-recurring costs of SEK 10 million were charged to the results for the year
as well as the impairment of intangible assets of SEK 74.6 million.
  · Loss after tax for the year was SEK 504.7 million (-13.6). The results were
charged with a decrease in value of the associated companies of SEK 414.7
million, of which SEK 0.7 million was charged to the fourth quarter, as well as
the impairment of intangible assets of SEK 74.6 million.
  · Loss per share for the year, basic and diluted, was SEK 7.23 (-0.16).
  · Equity per share was SEK 1.85 (33.43).
  · Equity/assets ratio was 54 (69) percent.

Key events in the fourth quarter

  · In October, the group implemented a rights issue in Allenex, resulting in an
increase of the company’s share capital of SEK 103.1 million. The issue
generated funds of around SEK 108.6 million before issue costs. In addition,
Allenex reduced its (”KV1”) convertible debt by SEK 44.1 million in an offset
against shares.
  · In October, AbSorber won patent protection in the U.S. for the diagnostic
transplantation cross-match test XM-ONE®.
  · At the annual ASHI congress held in mid-October in New Orleans, Allenex
presented its complete transplantation sector portfolio for the first time under
the new company name.
  · In November, the group implemented a directed offer to holders of
convertibles regarding early repayment of Allenex (”KV1”) convertibles at 100
percent of the nominal rate, equivalent to SEK 30 per convertible. Holders of
convertibles representing SEK 33.1 million accepted the offer, following which
the company’s outstanding convertible debt (”KV1”) is SEK 7.7 million. Repayment
was made at the end of January 2012.
  · The rights issue implemented by Allenex during the quarter resulted in that
the two largest shareholders in Allenex, Mohammed Al Amoudi and FastPartner AB
(publ), now own over 30 percent of the shares and votes in the company
respectively, thereby reaching the limit for a mandatory bid on the company.
Hence, a public takeover bid was made through Xenella Holding AB, jointly owned
by Mohammed Al Amoudi and FastPartner AB (publ), at the end of November to the
shareholders of Allenex for SEK 1.50 in cash per share. The offer valued all
outstanding shares in Allenex at a total of around SEK 180.4 million. The Board
of Directors of Allenex AB recommended shareholders not to accept Xenella
Holding’s offer.

Key events after the year-end

  · At the end of the period of application, Xenella Holding’s offer had been
accepted by shareholders representing 11,174,755 shares in Allenex, equivalent
to 9.3 percent of the shares and votes in the company.

CEO Anders Karlsson’s commentary on the fourth quarter 2011:
“The reshaping of Allenex into a global transplantation company is moving full
speed ahead. Our intention is to create a company with the capacity to generate
strong sales growth, while providing our customers with the best possible
support. Our organization for 2012 is now in place. We have a strong offering
and are market leader in all product segments. Sales growth is robust and our
products continuously win market share in this highly competitive market. This
growth has occurred in particular in the U.S. market, where we added several new
customers during the year, while all major accounts remain at least at the same
level as before.”

Allenex AB discloses the information provided herein pursuant to the Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 15:00 (CET) on February 23, 2012.

For more information, please contact:
Anders Karlsson, CEO, tel: +46 (0)70-918 00 10 or email
anders.karlsson@allenex.se